Stock Analysis of INmune Bio Inc (INMB) - Birds Eye View

1W   2W   1M   3M   1Y   2Y   5Y   
Overview
Code INMB
Close 10.85
Change -0.320 / 2.86 %
Volume 84727.00
Vol Change 20593.00 / 32.11 %
IndustryBiotechnology
SectorHealthcare
AIO Strength Index
Technical StrengthMild Bearish
Growth Index Poor Growth Stock
Value Index Poor Value Stock
Profitability Index Poor Profitability Stock
Stability Index Low Stability Stock


Fundamental View of INmune Bio Inc
PE (TTM)

3818.41

Very Poor
Price / Book

2237.87

Very Poor
Price / Sales

-546778.80

Very Poor
Piotroski F Score

3.0

Not Good
Market Cap

214639 K

Enterprise Value

188831 K

ROA (TTM)

41.20

Excellent
ROE (TTM)

59.27

Excellent
Net Margin (TTM)

-14319.55

Very Poor
Revenue

159.89 %

224000
Net Profit

0.491 %

-27433.00 K
Debt to Equity

0.269

Excellent
Altman Z Score

2.72

Indecisive
Quick Ratio

0

Poor
Cash Ratio

1.94

Indecisive


Highs/Lows of INmune Bio Inc
PeriodOld priceStock ReturnS&P 500 ReturnsHighLowHigh DateLow Date
One Week10.02 8.28 % 1.54 % 11.4659.6716-May-2413-May-24
Two Week11.57 6.22 % 3.42 % 11.75849.6706-May-2413-May-24
One Month8.43 28.71 % 5.60 % 12.728.330-Apr-2419-Apr-24
Three Month14.01 22.56 % 5.95 % 14.418.320-Feb-2419-Apr-24
Six Months7.41 46.42 % 17.48 % 14.747.224214-Feb-2420-Nov-23
One year7.41 46.42 % 27.52 % 14.746.509214-Feb-2420-Sep-23
Two year7.49 44.86 % 29.70 % 14.745.7514-Feb-2413-Oct-22
Five year10.82 0.277 % 85.46 % 14.742.214-Feb-2418-Mar-20


Technical View of INmune Bio Inc
RSI

50.38

Neutral
MACD

0.0137

Mild Bullish
ADX

15.20

Neutral
Super Trend

9.13

Mild Bullish
Williams %R

-61.31

Neutral
CCI

8.85

Neutral


EMA 5

10.87

Strong Bearish
EMA 15

10.80

Bullish
EMA 50

10.93

Whipsaw
EMA 100

10.83

Whipsaw
SMA 100

11.51

Mild Bearish
SMA 200

9.77

Mild Bullish
SMA 5 / 20

10.76 / 10.94

Bearish
SMA 15 / 50

11.02 / 10.88

Strong Bullish
SMA 50 / 200

10.88 / 9.77

Mild Bullish




Charts of INmune Bio Inc


Returns of INmune Bio Inc with Peers
Period / StockINMBKMPHCLLSVBLT
1 Week8.28%12.12%-2.29%1667.31%
1 Mth28.71%52.30%21.54%1002.80%
3 Mth-22.56%13.95%3.46%973.60%
6mth46.42%5.01%2.05%1306.63%
1 Year46.42%37.34%66.11%2105.60%
2 Year44.86%-27.28%-14.08%13.46%
5 Years0.277%-93.95%-83.99%102.72%
charts-
View All Together in Chart      Inline           Tile

Compare Fundamentals of INmune Bio Inc with Peers
Ratio / StockINMBKMPHCLLSVBLT
PE3818.41-5.46-1.6718.63
P/B2237.872.302.068.62
ROA41.20-33.53-41.9434.38
ROE59.27-42.06-124.8946.29
Debt To Equity0.2690.2050.4970.0251
Revenue224000
159.89 % 		10458.00 K
63.50 % 		16496.00 K
13.95 % 		658000
14.32 %
Net Income-27433.00 K
0.491 % 		-41543.00 K
385.60 % 		-85010.00 K
13.86 % 		-464000.00
98.45 %


Technicals of INmune Bio Inc with Peers
Technical / StockINMBKMPHCLLSVBLT-
ADX15.2027.2423.6425.68
CMF0.1150.0630.496-0.311
MFI43.7265.7767.9534.42
RSI50.3870.9555.0795.32
MACD Abv SignalTrueTrueTrueTrue
Price Above 50 MAFalseTrueTrueTrue-
Price Above 200 MATrueTrueTrueTrue-


About : INmune Bio Inc

Address : 225 NE Mizner Blvd., Boca Raton, FL, United States, 33432
Tel : 858 964 3720
URL : https://www.inmunebio.com
Code : INMB, ISIN : US45782T1051, Exchange : NASDAQ, Country : USA
Fiscal Year End : December
IPO date : 04_Feb_2019
Employee Count : 11

INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.


Note : All Data Generated at the End of Trading Hours (EOD Data)